ALK and rhabdomyosarcoma: Lastly, we show potent efficacy in an ALK-expressing rhabdomyosarcoma xenograft model RH-41 carrying the PAX3::FOXO1 fusion, a potent and canonical oncogenic driver of this often-lethal childhood sarcoma71.